Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542408 | 0.83 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL25373206 | 0.83 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL25373201 | 0.83 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL31642671 | 0.83 | RXRA (0.38) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL30922889 | 0.82 | RXRA (0.37) | RXRARXRBRXRGSLC6A3DGAT2 | |
| SCHEMBL30922527 | 0.81 | RXRA (0.39) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL31642907 | 0.81 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL30922407 | 0.80 | ALDH1A1 (0.39) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL31040992 | 0.79 | RXRA (0.34) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL31127808 | 0.79 | RXRA (0.38) | RXRARXRBRXRGDGAT2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | RXRA 1531/4885RXRB 1041/4885RXRG 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.